Interview with Hope Road hepatitis B hepatitis B treatment concerns double standard (a)

 Interview topics: attention to World Hepatitis Day double standard treatment of hepatitis B
invited guests: Chinese Academy of Engineering Professor
Zhuang Hui, vice chairman of China Foundation for Hepatitis Prevention and Control Miss Wang Zhao
302 Hospital of PLA
Following Professor Zhang Hongfei Record for the interview:
Click to view the content of users and the media's questions >>>>< br> Moderator: Sohu users Hello everybody, thank you, such as some health experts to the Sohu interview, the next Monday that is, May 19, 2008 is We have friends who go to the Chinese Academy of Engineering, Professor Hui Zhuang, Vice Chairman of China Foundation for Hepatitis Prevention and Control Miss Wang Zhao and treatment of hepatitis B artists, PLA 302 Hospital, Professor Zhang Hongfei, director of liver disease in the experts today talk shows, chat with you talk about a hot topic in the treatment of hepatitis mm how to achieve double-standard treatment of hepatitis B, an early withdrawal.
first of several guests with friends and say hello.
Zhuang Hui: Hello netizens.
Wang Zhao: Members User Hello everybody, I am pleased to have opportunity to share in the Sohu to exchange views on issues related to hepatitis.
cheong: netizens are you willing to join you and work to combat viral hepatitis.
Moderator: interview Visitors have more than a dozen friends in the mainstream media and professional, we welcome the arrival of the same.
In this interview, we also arranged the guests and the media and on-site users of the exchange time, please prepare your question, we at about 4 o'clock to answer your questions will focus on.
the origins of World Hepatitis Day and the theme
the following link to enter today's interview.'ve just been introduced, this year May 19 is the first World Hepatitis Day theme of Association launched the Global Hepatitis Day, mainly in Europe, and later once a year, increasing scale, to the November 4, 2007 establishment of the World Hepatitis Alliance World Hepatitis Alliance, taking into account the more serious viral hepatitis in the world, decided to an annual event initiated by the World Hepatitis Day. World Hepatitis Day aims to appeal to the general public to strengthen the understanding and prevention of viral hepatitis.
Moderator: We just talked about this year's theme is I am a you billion, which more than five hundred million people the equivalent of the global population of 1 / 12. alert the public to understand viral hepatitis, take some other way to avoid the risk of viral hepatitis as much as possible.
Zhuang Hui: Viral hepatitis is more serious, the incidence is relatively hidden, and not easy to find, not easy by early diagnosis and early treatment. Now our nation is patient with chronic hepatitis B, chronic hepatitis B virus infection of 93 million people, significantly more than the original 120 million reduction to reduce the number nearly three million, but still large number of 93 million , the problem is quite serious. 30 million people died in China every year from diseases associated with hepatitis B, hepatitis B and hepatitis C is a serious disease in our country, it is worth attention.
China Hepatitis Prevention and Control Foundation, what work to do ?
Moderator: as the first World Hepatitis Day, we also have Foundation for Hepatitis Prevention and Control from China, Miss Wang Zhao, vice president, please tell us about Hepatitis Prevention and Control Foundation, formed in the course of hepatitis done at which promote the work, what they intend to do other work to create public awareness of the disease.
China Foundation for Hepatitis Prevention and Control
Wang Zhao Wang Zhao, vice president: Professor Hui Zhuang just have to introduce the hepatitis B in particular, hepatitis B, hepatitis C, which is widely popular around the world, the disease state, the population is already endangered the world's population accounts for 1 / 12. each country the prevalence of hepatitis and the actual degree of harm there is a difference in the Europe's leading hepatitis C infection or a more serious epidemic is more prominent, so they are there in the past few years, special emphasis should be raised for the hepatitis C awareness for early detection and diagnosis of hepatitis C treatment should be given attention, in particular, to urge the national government to give policy support. Therefore, the main patient organizations, launched the world's first hepatitis C together at such an event.
For China, China's hepatitis C is very serious to the data currently available point of view, than the global average even higher infection levels, but these patients where? is not their own I know that is not all medical treatment, and these situations they may not grasp. and more dangerous than the more prominent of hepatitis C is hepatitis B, hepatitis B infection and the incidence of China are very, very serious, for it is the prevalence of infection, the past that we are living in a global level areas of high prevalence of hepatitis B in recent years because of adherence to hepatitis B vaccine for newborns inoculation, the small age group infected with HBV infection has significantly reduced the level of the whole population the average carrier rate of hepatitis B surface antigen levels decreased, but still there are over ninety million people living with HIV, this is a very large number .
how can the hepatitis prevention, control, scientific research to improve all aspects of the degree of attention to it, increase its prevention efforts, these are very tight in front of us is very important to very real problems. Now we situation, although these years the popularization of knowledge of hepatitis, skills training, to do some work, but there are a lot of people for hepatitis B, hepatitis C or hepatitis A, hepatitis E are not very understanding.
Moderator: There are a lot because Hepatitis B is relatively large base of people, there is discrimination or some people do not correctly understand the disease.
Wang Zhao: Knowledge of hepatitis due to lack of understanding how infectious, his how if the infection of hepatitis should be treated properly, how can we not infected by other people, a lot of the general public awareness of the errors, just like you said, there are many incorrect behavior, but also the psychological impact of the spirit of some people or even a normal life, social activities and so on.
Although hepatitis is a disease, it is not only harmful to human health, but also gives the physical, mental, spiritual, and normal social life and even cause some considerable damage. because of rejection, misunderstanding, discrimination of these Some actions should not be there, some people infected with hepatitis when he would at the very low after the state, and even lead to further education, employment, marriage, family, children, conflict, etc., causing many social problems.
Moderator : We will do the work of the liver is based mainly in the promotion of public education than this one?
Wang Zhao: China Foundation for Hepatitis Prevention and Control through a lot of work, the organization and implementation of various projects, more and more deeply appreciate the publicity education, social mobilization is the prevention and treatment of hepatitis, hepatitis is very important to control an area. Back in 2006 a proposal of experts, hope to have a centralized outreach opportunities hepatitis knowledge, the proposed date of the establishment of a love of the liver, experts We suggested to the chairman of the Chinese Foundation for Hepatitis Prevention and Control, Comrade He Luli, where she attached great importance to this issue, let us solicit opinions and then follow the procedure to see to the competent authorities can not be declared president of the Foundation according to the requirements of any directions we have The corresponding work done, the majority of medical workers, especially hepatitis and liver disease expert is very much supportive.
then we devoted to the Ministry of Health in charge of our written reports should be said that the leadership of the Ministry of Health still very supportive of this recognition recommended, but because it was the Ministry of Health for the Day, Day, holidays approval can not operate independently, need the State Council to grant the NPC Standing Committee, and later taking into account that such an application may have some difficulty, and therefore no. but we feel called to love one or liver at, or called on this form of hepatitis is still very good very necessary, because we have a lot of focus on infectious diseases have taken a similar form, received very good results. such as the December 1 of the AIDS Day, March 24 TB Day, and Love Teeth Day Sight Day, Ear Care Day, May 31 No Tobacco Day is right, these are very good publicity in the form, Therefore, we are willing to learn from their successful experiences, to promote expansion of the hepatitis, can strike deep roots and can have a very intensive propaganda for everyone to impress.
in our country has not been formally approved, abroad by the European The patient organizations initiate and hope that we can participate in to support, and of course we are happy, we are actively involved in this event. regardless of the World Hepatitis Alliance or the Chinese Foundation for Hepatitis Prevention, the reason why we launched the Hepatitis Day to promote the establishment of the fundamental purposes or to the whole society can cause hepatitis, including hepatitis B, hepatitis C, including the concern of hepatitis and hepatitis Government can promote the prevention, control and scientific research, staff training, patient care, etc., to take stronger measures to promote the work of real depth.
5 �� 19 Day World Hepatitis Day What are the specific activities?
Moderator: king of the executive director just through the introduction, although it is very simple, in the May 19 That day we will have some activities to promote hepatitis-related knowledge, but in fact the anniversary does not come easily. Our Foundation for Hepatitis Prevention and Control of hepatitis during the day or what the highlight of May?
Wang Zhao : 19 May by the World Hepatitis Alliance launched the first global World Hepatitis campaign, the ultimate goal of the World Hepatitis Alliance hope to get official recognition, can be supported by the World Health Organization. They also set up the process of Hepatitis Day played a role in many world renowned experts, such as our Zhuang Hui is a Fellow of the World Hepatitis Alliance Public Health and a member of the Committee of Experts, including the World Hepatitis Alliance World Hepatitis Day campaign to provide expert advice to support.
In the May 19 event has been arranged, the morning of the Summit will be held in viral hepatitis, of course, not a professional academic conference, but a social mobilization, people can go together to participate in all aspects, the report by experts to be able to give us a brief summary of all about China, including global prevalence of hepatitis present, control the progress of work, currently facing a problem, how should we address these issues do offer some suggestions. At the same time the afternoon of May 19 we will have a For World Hepatitis Day PR campaign to promote common interest of hepatitis, of course, the form and not the same as sitting in a meeting inside City Hall, more lively and richer.
5 �� 19 �� day's activities to combat hepatitis B in China Foundation to carry out the main, these activities have also been many experts there are the health system in the health sector and related public health workers support the organization, there are many business partners for their activities on May 19 offers financial support, manpower support, in order to organize this event also made many good suggestions. now because of the earthquake disaster relief is the most important tasks, meeting the entire project may be compared with a slight adjustment of the original change We asked the Ministry of Health was held as scheduled.
in the before and after May 19 we will launch a series of promotional activities, these activities are mainly carried out by the Foundation and a number of projects for the students knowledge of health education programs hepatitis to start, women of childbearing age hepatitis health education project to summarize the primary vaccine should summarize the project, to demonstrate results, promotion experience. At the same time on May 19 followed by a period of time through both the Chinese Foundation for Hepatitis Prevention and Control a patient education program, one is .
Moderator: This is nationwide?
Wang Zhao: nationwide. involving very large cities and hospitals, are now prepared to related work has been basically completed. business partners in this has also given us great help, made a very careful arrangements, promotional materials, posters, T �� publicity material have been gradually distributed to various publicity points and the hospital. take the form of propaganda that the range of relatively arrangement than a single larger number of activities that may effect the response received will be better.
Moderator: Thank you, Chairman Wang's introduction, we also know that in the May 19 events in the Great Hall, Sohu health also Forum will be broadcast in the day, if we never get to the Great Hall of the event can go to the online concern. In the afternoon of May 19 should be said that the activities carried out in the world-renowned Great Wall, if you must travel to the Great Wall look the day's activities, there is no chance for the Foundation for Hepatitis Prevention and Control Web site also know the day the health situation of Sohu.
immunization hepatitis B vaccine should also pay attention to young outstanding achievements of hepatitis B vaccination
Moderator: just king Fellow director and Zhuang Hui introduced indeed the case of hepatitis B is still very serious, almost a billion people, this is 2008, the results of the Ministry of Health statistics. our side to get the data in April 2008, Health the latest survey released by the Ministry of hepatitis B, the results show that the country 1-59 years of hepatitis B surface antigen carrier rate 7.18% of 1992 and survey of hepatitis B surface antigen carrier rate 9.75%. basis of this calculation, China has about hepatitis B surface antigen carriers 9300 million. which 1 to 4 years of hepatitis B surface antigen carrier rate of the lowest, to 14 .5 0.96% 2.42% .15-year-olds to 59-year-olds carry the highest rate of hepatitis B surface antigen, at 8.57%. In terms of vaccination , 1 to 4 years and 5 to 14 years survey of hepatitis B vaccine coverage rate was 89.39% and the whole 50.59%. Several guests can not give answers to what users, such results suggest that what?
Fellow
Zhuang Hui Zhuang Hui: our country from 1992 to the hepatitis B vaccine on neonatal immunization administration, management is the so-called neonatal immunization from January 1, 1992 start to the hepatitis B vaccine, the cost of the vaccine by parents .2002 paid to hepatitis B vaccine began formally incorporated into the national immunization program and the parents do not pay the cost of the vaccine, just pay a small service fee for services rendered after .2005 do not have to pay, free of charge by.
1992 when the survey hepatitis B surface antigen carrying rate 9.75%, in 2006 hepatitis B surface antigen carrier rate decreased to 7.18%, less thirty million carriers of hepatitis B surface antigen, the credit due to the immunization of hepatitis B vaccine, especially for new students children with hepatitis B vaccine, so you can see 0m4-year-olds carrying rate of hepatitis B surface antigen is now less than 1%, has reached the World Health Organization's goal by 2010, children under 5 years of hepatitis B surface antigen carrier rate to reach 2% or less, and now we have reached the 1%, the World Health Organization has reached the goal, with our newborn hepatitis B vaccination is between .15 some years, we have to hepatitis B vaccine sectors, especially the vaccination of newborns has made great achievements.
part, but on the other hand we have children do not replant, there are young people at high risk of vaccination vaccination has not made this a very good immune strategy. the future of children replant should be strengthened, if the neonatal period did not receive hepatitis B vaccine, then replant in childhood should be. youth more active sex life because of infection of hepatitis B opportunities, if not hepatitis B in the neonatal period vaccine, when young people should replant. There is also a high risk of vaccination should be strengthened.
hepatitis B surface antigen carrying children has decreased, but the adult hepatitis B virus, chronic hepatitis is still considerable number of people, which some people need treatment, according to their condition, and if aggressive treatment of chronic hepatitis B should be, if it is to conduct regular monitoring of carrier, if the liver function is not normal and hepatitis have demonstrated that active treatment of patients .
country has more than 2000 million carriers of hepatitis B patients needed to treat the rest of the need for regular monitoring of
Moderator: We also know that there are many of the standard hepatitis B is divided into different classes, we are among 9300 people what constitutes kind of features?
Zhuang Hui: 93 million chronic hepatitis B virus infection, there is still a quarter of patients with chronic hepatitis B, this part of the patient is in need of treatment, their liver function is not normal, hepatitis The clinical symptoms and signs, liver function tests if there is to do some lesions, this part of the patient is over twenty million. two more than ten million patients can be divided into two categories, one is E antigen positive, and there is a class E antigen negative, regardless of E antigen is positive or negative chronic hepatitis B patients are in need of treatment.
there are three-quarters of people with chronic hepatitis B virus infection, is more than sixty million, which people are carrying hepatitis B virus, with normal liver function, no signs and symptoms of hepatitis, you can work and study as usual, this part of the patient is not treated, there is no medicine of hepatitis B virus can be cleared, but need to the hospital every six months time to see if liver function is normal, is not chronic hepatitis B carriers than patients with chronic hepatitis B patients if it is not only carrying hepatitis B virus, and that these people still need treatment. But once develop into chronic hepatitis B patients on the need for treatment. < br> more than two thousand million people in need of treatment for chronic hepatitis B patients, other people are chronic carriers of hepatitis B virus, only to be seen without treatment.
part of chronic hepatitis B can be cured
Moderator: Mr Zhuang Yuanshi that 9300 million people, of which 1 / 4 of the people are certainly in need of treatment, and now we advocate a very important point is that standard treatment, Zhuangyuan Shi-sponsored by China in recent years, Prevention Guide China's hepatitis B virus replication and delay the development of the disease, reduce liver failure, cirrhosis and liver cancer incidence and improve the quality of life of patients.
from now, we are now the treatment of chronic hepatitis B to antiviral therapy is Lord, drugs, including interferon, adefovir, lamivudine, telbivudine and other five drugs. If the specification to antiviral treatment, some patients can still be cured, some patients need long-term treatment, anti- the virus does not mean that lifetime use of drugs, such as Professor Zhang also mentioned a while.
some patients after treatment for some time to achieve the treatment goals, E antigen positive patients after treatment by anti-virus E antigen negative a, E antibody positive, and ALT normal, to such a degree a year later to continue treatment as long as it remains the same to be discontinued, and these patients are stable, a small number of patients may relapse, recurrence, then further treatment. some of the long term surface antigen negative patients, the occurrence of surface antigen seroconversion, so that patients can be said to be clinically cured, does not mean suffering from hepatitis B will never get better by. there are still some worthy of note that 93 million chronic hepatitis B virus infected persons, an annual 0.5% m1% of people will naturally negative surface antigen, surface antibody positive, not to say impossible to cure, not all develop into liver cancer, cirrhosis of the liver, which is wrong understanding.
will give this year's European hepatitis in the treatment of liver disease brings hope
Moderator: It should have a short-term goal that we have a long-term goal is to put the virus under control recently, long-term goal is not to develop into cirrhosis of the liver and liver failure. Professor Zhang Hongfei, a hepatitis B treatment is all that we held last month in Europe's liver will, Professor Chang is also on site, and can not tell us something about the treatment of hepatitis B liver disease have the annual meeting of the new ideas or new methods?
PLA 302 Hospital, Professor Zhang Hongfei
cheong: just Zhuangyuan Shi and Wang Director introduced the general situation about hepatitis, hepatitis in fact our country for three blocks, a basic knowledge of the masses of hepatitis education popular one is the prevention of disease, a treatment for the disease, the former Secretary spoke two Zhuangyuan Shi and Wang are very clear that we work in recent years, considerable progress has been made. But everyone, especially the last piece of the patient is more concerned with disease treatment.
annual meeting of the European liver disease worldwide each year two of the most prestigious academic conference on one of liver disease, a liver disease in the United States will, one annual meeting of the European Liver .4 21 in Europe held in Milan, Italy 43 th annual meeting of the European liver disease, can be said that this meeting gives us hope, that hope can be divided into three parts.
first part simply just like Zhuangyuan Shi said, hepatitis B there is a cure for it? this meeting revealed a clear message, there are many papers in this area, national experts in these areas also done a lot of work and try. Hepatitis B through long-term treatment of a reasonable standard, some patients do see in recent years has reached from the cure, but only a small part, albeit a small part, but give us hope and the dawn. For liver disease patients is concerned, the kind of pessimistic thinking should be abandoned.
second, specific to hepatitis B treatment goals with a new formulation, in the past generally considered normal transaminases is cured, then later discovered that this does not work, from the advent of antiviral drugs have hepatitis B virus DNA after negative, we think that we think HBVDNA negative cured, this meeting made it clear once again that we can achieve a feasible target now should be double standards. This double standard is HBVDNA the negative connotation of E antigen coupled with the disappearance of or seroconversion, disappearance of the E antigen seroconversion to a higher awareness of, and after antiviral therapy can indeed achieve the treatment of 30% to 50% of patients can obtain E antigen negative, and seroconversion . The third goal is to cure, we now have a small number of people can reach the surface antigen negative and seroconversion.
our layman's terms with the Olympics, HBVDNA the negative is getting the bronze medal, E antigen transfer conversion of yin and blood serum was silver, the surface antigens into the blood serum and disappear we got the gold medal. Now we've picked grab gold silver bronze war, and perhaps another two or three years we can achieve the disappearance of the liver inside the viral template. In short, the last five to ten years for the treatment of hepatitis B hepatitis C treatment, including rapid changes have taken place, and constantly give us good news, ladies and hepatitis Ye Hao, family friends and relatives of hepatitis patients, but for me think we should pull themselves together , speaking as president of Zhuangyuan Shi and Wang, common in order to control its efforts to achieve the final victory.
Third, why do some E antigen negative, and some surface antibody negative, we focus in this three questions on the choice of antiviral drugs, application, individual therapy, and some new treatment ideas, our requirements are not aware of this drug, and use good or not good to use other, this is our meeting a large number of articles which Some drugs we think that 50 years of interferon, nucleoside analogues for ten years, is not commonplace? not. The efficacy of interferons, nucleoside analogues from the first, second, third, Fourth, there are still a dozen research, what are the advantages of these drugs have any shortcomings, in the end how to choose, how to use, this meeting gave us a further new information. Medical certificates are seeking this information is not to say one or two patients, but rigorous scientific experiments confirmed that the drug based on scientific research, the European Liver will simply say that in these three areas. we can be Good to know and learn.
telbivudine than other nucleoside drugs have a higher rate of E antigen seroconversion
Moderator: Focus on the person listening to this interview after the news much encouraged, just three guests have emphasized the anti-viral treatment for hepatitis B is very important on the one hand, I remember professors have said, the discovery of interferon should be said is a milestone in the treatment of viral hepatitis, has just told nucleoside Zhang analogues were found ten years time, there are two three four generations of products, What are the advantages nucleoside analogues in the end what are the disadvantages, especially for patients when the treatment of individual areas which can draw on?
cheong: I just noticed on the antiviral Zhuangyuan Shi talked about, the host also spoke a bit, everyone's understanding of the present and not fully in place. king of the lead director to do a survey, a better understanding of antiviral therapy for patients about less than 50%, meaning that less than half of the patients knew the urgent need antiretroviral treatment. Our daily contact with many patients, they are almost three months for a check, semi-annual inspection, continuous examination of the ten years, has been eating JiangMei medicine, liver medicine, tonic, etc., the result is vomiting blood come to us. speak before anti-viral treatment of hepatitis is also necessary to explain the bottleneck is the anti-virus, if capacity allows us to take into account the economic, anti-virus is to solve the problem of survival, and comprehensive treatment of the problem is essentially a well-off, first to emphasize hepatitis B, hepatitis C antiviral therapy.
In this context, we speak of anti-hepatitis B virus therapy, nucleoside analogues antiviral therapy has been very familiar with everyone, and now the four drugs in the domestic market in the international market of about five, the four drugs are telbivudine, entecavir, adefovir and lamivudine This is all of four common drugs that inhibit the hepatitis B virus nucleic acid synthesis, these drugs are drugs that suppress the virus.
these four drugs and some details of the different, such as the role of some drugs is very fast and very strong inhibition of the virus. inhibit the virus is very strong, the role of fast three drugs, telbivudine, entecavir, lamivudine, but the early occurrence of lamivudine resistance, the incidence is relatively high, which is the difference between in other important characteristics of two types of drugs.
Furthermore, all the nucleoside analogues compared with interferon for viral nucleic acid suppression fast, but a withdrawal to relapse. The liver of a large number of European articles, Although the non-head to head study, we found that nucleoside analogues which have drugs on the E antigen E antigen negative, and seroconversion rate is relatively high, and gives us some hope, such as the article is more concentrated for the telbivudine, and its E antigen seroconversion rates relative to other nucleoside analogues from the literature is relatively high probability of view, and in some people can even reach 36% m40%.
resistant chronic hepatitis B patients viral therapy for at least take two years to achieve viral suppression and E antigen seroconversion
Moderator: Professor Zhang has just talked about two types of antiviral drugs, especially in terms of what the radio Gan similar advantages, disadvantages and similarities, before Zhuangyuan Shi talked about the then proposed to achieve the goal of treatment of chronic hepatitis B, there are some standards, such as transaminase levels, E antigen negative, Zhuang Yuanshi give us to talk about which indicators to our patients, when prompted, or check out What time of withdrawal or treatment for a long time, or like we've got to understand hepatitis B is a lifetime thing?
Zhuang Hui: key to the treatment of chronic hepatitis B virus is the antiviral treatment, according to a 2004 survey only 19% of chronic Hepatitis B patients are anti-viral treatment, most patients no antiviral therapy, which requires our attention, need to vigorously promote. chronic hepatitis B patients to antiviral treatment, antiviral treatment is the key. According to our survey 37% of patients to antiviral treatment, 63% of patients still do not know to antiviral therapy of chronic hepatitis B, which also requires us to step up publicity, so that patients understand the treatment of chronic hepatitis B have anti-virus. This is the first II.
Third, chronic hepatitis B patients receiving antiviral therapy, 40% short-term treatment of patients that can be cured, it also requires us to step up publicity. antiviral therapy short term treatment is not enough, need long-term treatment . From the research point of view at home and abroad, E antigen positive chronic hepatitis B patients by only 20% of the patients to consider withdrawal of treatment for two years, 80% of the E antigen positive patients can not be discontinued even after two years continue treatment. E antigen-negative patients to 100% of patients treated at least two years, patients and doctors should be aware of this.
our guidelines clearly written inside, E antigen positive chronic hepatitis B patients treated to be discontinued when it? undetectable after treatment HBVDNA a, E antigen negative a, E antibody positive, and we called the E antigen seroconversion, and ALT normal, liver biopsy was normal, reaching the four indicators should continue treatment after one year, check twice, if you examine the four indicators of the two still maintain the same, we can consider stopping. E antigen positive patients, only 20% of patients can be considered two years after treatment withdrawal. there 80% E antigen-positive patients may require longer treatment.
E antigen negative hepatitis B virus DNA in patients was positive, ALT is not normal, liver biopsy the lesion, the treatment to what time may consider withdrawal? our country, should continue the treatment year and a half, check the three or the maintenance of these three parameters remain unchanged, hepatitis B virus nucleic acid was negative, ALT normal, minor lesions or normal liver biopsy, this time to consider stopping. E antigen negative chronic B 100% of hepatitis patients need treatment more than two years, after which they continue to target one and a half year of treatment these patients reach these three indicators, it is estimated more than two years, so fight a protracted war. chronic hepatitis B short-term treatment of hepatitis patients do not like that, and be sure to listen to the doctor, long-term treatment has been to reach the target date, the same check twice or three times a withdrawal can be considered.
the treatment of chronic hepatitis B how to do individual therapy? < br> Moderator: Thank you Zhuangyuan Shi, I would like to ask Professor Zhang Hongfei, just Zhuangyuan Shi told us to meet a lot of years when the indicators proposed by you just get caught gold silver bronze war, through what in terms of clinical kind of a way to achieve this level?
cheong: Clinically speaking a lot, we probably have three more attention.
First, accurate comprehensive assessment of the patient to do. For example you are a patient with liver cirrhosis , then your medication, your response to therapy, adverse reactions after treatment and the treatment of hepatitis patients and the general efficiency and certainly not the same. If you are a mild or moderate ...